1. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes
- Author
-
Darryl J. Burstow, F. B. Ross, Andrew S. Hoey, Leslie Ong, Michael Wei, Maree T. Smith, Lindsay Brown, and Katrina L. Schmid
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,endocrine system diseases ,business.industry ,Diastole ,nutritional and metabolic diseases ,medicine.disease ,Streptozotocin ,Nephropathy ,Endocrinology ,Cataracts ,Internal medicine ,Diabetes mellitus ,Neuropathic pain ,medicine ,Cardiology and Cardiovascular Medicine ,business ,Polyneuropathy ,medicine.drug ,Retinopathy - Abstract
Background: Diabetes in humans induces chronic complications such as cardiovascular damage, cataracts and retinopathy, nephropathy and polyneuropathy. The most common animal model of human diabetes is streptozotocin (STZ)-induced diabetes in the rat. Methods: This project assessed cardiovascular, ocular and neuropathic changes over a period of 24 weeks post STZ administration in rats. Results: STZ-diabetic rate (n=96) showed stable signs of diabetes (hyperglycaemia, increased water and food intake with no increase in bodyweight): 52% of untreated STZ-diabetic rats (n=50) survived 24 weeks after STZ administration. STZ-diabetic rats were normotensive with slowly developing systolic and diastolic dysfunction and an increased ventricular stiffness. Ventricular action potential durations were markedly prolonged. STZ-diabetic rats developed stable tactile allodynia. Cataracts developed to presumed blindness at 16 weeks but proliferative retinopathy was not observed even after 24 weeks. Conclusion: The chronic STZ-diabetic rat mimics many but not all of the chronic complications observed in the diabetic human. The chronic STZ-diabetic rat may be a useful model to test therapeutic approaches for amelioration of chronic diabetic complications in humans.
- Published
- 2003